Endometriosis Trial: Study of NBI-56418 in Endometriosis
Public ClinicalTrials.gov record NCT00109512. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.
Study identification
- NCT ID
- NCT00109512
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 49 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2005
- Primary completion
- May 31, 2006
- Completion
- May 31, 2006
- Last update posted
- Feb 21, 2012
2005 – 2006
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 56266 | Phoenix | Arizona | 85032 | — |
| Site Reference ID/Investigator# 55210 | San Diego | California | 92103 | — |
| Site Reference ID/Investigator# 55214 | San Ramon | California | 94566 | — |
| Site Reference ID/Investigator# 56267 | Clearwater | Florida | 33759 | — |
| Site Reference ID/Investigator# 56270 | Champaign | Illinois | 61820 | — |
| Site Reference ID/Investigator# 56273 | Chicago | Illinois | 60612 | — |
| Site Reference ID/Investigator# 56269 | Oak Brook | Illinois | 60523 | — |
| Site Reference ID/Investigator# 56271 | Peoria | Illinois | 61615 | — |
| Site Reference ID/Investigator# 56272 | Louisville | Kentucky | 40291 | — |
| Site Reference ID/Investigator# 55213 | Winston-Salem | North Carolina | 27103 | — |
| Site Reference ID/Investigator# 55211 | Arlington | Texas | 76012 | — |
| Site Reference ID/Investigator# 56268 | Sandy City | Utah | 84070 | — |
| Site Reference ID/Investigator# 56274 | Richmond | Virginia | 23294 | — |
| Site Reference ID/Investigator# 55212 | Virginia Beach | Virginia | 23451 | — |
| Site Reference ID/Investigator# 56275 | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00109512, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2012 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00109512 live on ClinicalTrials.gov.